blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3825403

EP3825403 - METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN(A) EXPRESSION [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  11.03.2022
Database last updated on 13.07.2024
FormerThe application has been published
Status updated on  23.04.2021
Most recent event   Tooltip27.04.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
[2021/21]
Inventor(s)01 / CROOKE, Rosanne, M.
2855 Gazelle Ct.
Carlsbad, CA 92010 / US
02 / GRAHAM, Mark, J.
2855 Gazelle Ct.
Carlsbad, CA 92010 / US
03 / FREIER, Susan, M.
2855 Gazelle Ct.
Carlsbad, CA 92010 / US
 [2021/21]
Representative(s)Leitner, Laura
Novartis Pharma AG
Lichtstrasse 35
4056 Basel / CH
[N/P]
Former [2021/21]Larbig, Karen Dorothee
Novartis Pharma AG
Patent Department
4002 Basel / CH
Application number, filing date20212913.623.05.2013
[2021/21]
Priority number, dateUS201261651539P24.05.2012         Original published format: US 201261651539 P
[2021/21]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3825403
Date:26.05.2021
Language:EN
[2021/21]
Type: A3 Search report 
No.:EP3825403
Date:08.09.2021
Language:EN
[2021/36]
Search report(s)(Supplementary) European search report - dispatched on:EP09.08.2021
ClassificationIPC:C12N15/113, A61P3/00, A61P9/00, A61P9/10, A61P29/00
[2021/21]
CPC:
C12N15/113 (EP,IL,RU,US); C07H21/00 (IL,KR,RU); A61K31/7115 (IL,KR,RU);
A61K31/7125 (IL,KR,RU); A61K48/00 (IL,KR,RU); A61P29/00 (EP,IL);
A61P3/00 (EP,IL,RU); A61P39/00 (IL,RU); A61P9/00 (EP,IL,RU);
A61P9/10 (EP,IL,RU); C07H21/02 (IL,KR,RU); C07H21/04 (IL,KR,RU);
C12N15/00 (IL,KR,RU); C12Y304/21007 (EP,IL,RU,US); C12N2310/11 (EP,IL,RU,US);
C12N2310/315 (EP,IL,RU,US); C12N2310/32 (IL,RU,US); C12N2310/321 (IL,US);
C12N2310/3231 (IL,US); C12N2310/3341 (EP,IL,RU,US); C12N2310/34 (IL,US);
C12N2310/341 (IL,US); C12N2310/346 (EP,IL,RU,US); Y02P20/55 (IL,KR) (-)
C-Set:
C12N2310/321, C12N2310/341, C12N2310/3525 (US,EP);
C12N2310/321, C12N2310/3525 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/15]
Former [2021/21]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODULATION DER APOLIPOPROTEIN(A)-EXPRESSION[2021/21]
English:METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN(A) EXPRESSION[2021/21]
French:PROCÉDÉS ET COMPOSITIONS DE MODULATION DE L'EXPRESSION DE L'APOLIPOPROTÉINE(A)[2021/21]
Examination procedure04.03.2022Amendment by applicant (claims and/or description)
09.03.2022Examination requested  [2022/15]
09.03.2022Date on which the examining division has become responsible
Parent application(s)   TooltipEP13793955.9  / EP2855500
EP20180985.2  / EP3822352
Fees paidRenewal fee
09.04.2021Renewal fee patent year 03
09.04.2021Renewal fee patent year 04
09.04.2021Renewal fee patent year 05
09.04.2021Renewal fee patent year 06
09.04.2021Renewal fee patent year 07
09.04.2021Renewal fee patent year 08
13.05.2021Renewal fee patent year 09
26.04.2022Renewal fee patent year 10
27.04.2023Renewal fee patent year 11
26.04.2024Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XDI]WO2005000201  (ISIS PHARMACEUTICALS INC [US], et al) [XD] 7-18,20-23 * pages 39, 49ff; examples 20, 23; claims 1-28, 32-49; tables 4, 7; sequences 11, 13, 16, 89 * * the whole document * [I] 1-20;
 [XDI]  - ESTHER MERKI ET AL, "Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 57, no. 15, doi:10.1016/J.JACC.2010.10.052, ISSN 0735-1097, (20101018), pages 1611 - 1621, (20110226), XP028407468 [XD] 7-18,20 * the whole document * [I] 1-23

DOI:   http://dx.doi.org/10.1016/j.jacc.2010.10.052
 [A]  - GIUSEPPE LIPPI ET AL, "Antisense therapy in the treatment of hypercholesterolemia", EUROPEAN JOURNAL OF INTERNAL MEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 22, no. 6, doi:10.1016/J.EJIM.2011.06.015, ISSN 0953-6205, (20110629), pages 541 - 546, (20110712), XP028105485 [A] 1-23 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ejim.2011.06.015
by applicantWO9414226
 WO9839352
 US5877022
 WO9914226
 US6268490
 WO03004602
 WO03014397
 US6525191
 US6670461
 US6770748
 US2004171570
 US6794499
 WO2004106356
 WO2005000201
 WO2005021570
 US2005130923
 US7034133
 US7053207
 WO2007134181
 US2008039618
 US7399845
 WO2008101157
 US7427672
 WO2008150729
 WO2008154401
 WO2009006478
 US2009012281
 US7547684
 US7696345
 US8138328
    - KRAFT et al., Eur J Hum Genet, (19960000), vol. 4, no. 2, pages 74 - 87
    - SCHULTZ et al., PLoS One, (20100000), vol. 5, page el4328
    - BERGMARK et al., J Lipid Res, (20080000), vol. 49, pages 2230 - 2239
    - TSIMIKAS et al., Circulation, (20090000), vol. 119, no. 13, pages 1711 - 1719
    - KOSCHINSKYMARCOVINA, Curr Opin Lipidol, (20040000), vol. 15, pages 167 - 174
    - RIFAI et al., Clin Chem, (20040000), vol. 50, pages 1364 - 71
    - ERQOU et al., JAMA, (20090000), vol. 302, pages 412 - 23
    - KAMSTRUP et al., Circulation, (20080000), vol. 117, pages 176 - 84
    - CLARKE et al., NEJM, vol. 2009, no. 361, pages 2518 - 2528
    - SOLFRIZZI et al., J Neurol Neurosurg Psychiatry, (20020000), vol. 72, pages 732 - 736
    - MERKI et al., JAm Coll Cardiol, (20110000), vol. 57, pages 1611 - 1621
    - Arch. Int. Med., (19880000), vol. 148, pages 36 - 39
    - FREDRICKSONLEE, Circulation, (19650000), vol. 31, pages 321 - 327
    - FREDRICKSON et al., New Eng J Med, (19670000), vol. 276, no. 1, pages 34 - 42
    - YUAN et al., CMAJ, (20070000), vol. 176, pages 1113 - 1120
    - JAMA, (20010000), vol. 285, pages 2486 - 2497
    - LEUMANN, Bioorg. Med. Chem., (20020000), vol. 10, pages 841 - 854
    - WOOLF et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 7305 - 7309
    - GAUTSCHI et al., J. Natl. Cancer Inst., (20010300), vol. 93, pages 463 - 471
    - "GENBANK", Database accession no. NT 025741.15
    - ELAYADI et al., Curr. Opinion Invest. Drugs, (20010000), vol. 2, pages 558 - 561
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, no. 403, page 410
    - ZHANGMADDEN, Genome Res., (19970000), vol. 7, no. 649, page 656
    - SMITHWATERMAN, Adv. Appl. Math., (19810000), vol. 2, no. 482, page 489
    - CHATTOPADHYAYA et al., J. Org. Chem., (20090000), vol. 74, pages 118 - 134
    - SINGH et al., Chem. Commun., (19980000), vol. 4, pages 455 - 456
    - KOSHKIN et al., Tetrahedron, (19980000), vol. 54, pages 3607 - 3630
    - WAHLESTEDT et al., Proc. Natl. Acad. Sci. U. S. A., (20000000), vol. 97, pages 5633 - 5638
    - KUMAR et al., Bioorg. Med. Chem. Lett., (19980000), vol. 8, pages 2219 - 2222
    - SINGH et al., J. Org. Chem., (19980000), vol. 63, pages 10035 - 10039
    - SRIVASTAVA et al., J. Am. Chem. Soc., (20070000), vol. 129, no. 26, pages 8362 - 8379
    - BRAASCH, Chem. Biol., (20010000), vol. 8, pages 1 - 7
    - ORUM et al., Curr. Opinion Mol. Ther., (20010000), vol. 3, pages 239 - 243
    - FRIEDEN, Nucleic Acids Research, (20030000), vol. 21, pages 6365 - 6372
    - FREIER et al., Nucleic Acids Research, (19970000), vol. 25, no. 22, pages 4429 - 4443
    - ALBAEK et al., J. Org. Chem., (20060000), vol. 71, pages 7731 - 7740
    - BAKER et al., J. Biol. Chem., (19970000), vol. 272, pages 11944 - 12000
    - MARTIN, Helv. Chim. Acta, (19950000), vol. 78, pages 486 - 504
    - ALTMANN et al., Chimia, (19960000), vol. 50, pages 168 - 176
    - ALTMANN et al., Biochem. Soc. Trans., (19960000), vol. 24, pages 630 - 637
    - ALTMANN et al., Nucleosides Nucleotides, (19970000), vol. 16, pages 917 - 926
    - SANGHVI, Y.S.CROOKE, S.T.LEBLEU, B., edsAntisense Research and Applications, CRC Press, (19930000), pages 276 - 278
    - JONES, L.J. et al., Analytical Biochemistry, (19980000), vol. 265, pages 368 - 374
    - LIPPI et al., Clinica Chimica Acta, (20110000), vol. 412, pages 797 - 801
    - FRAZER, K.A. et al., Nat. Genet., (19950000), vol. 9, pages 424 - 431
 US19740609895
 US19950610269
 US19980610269
 US19640610565
 US19870610977
 US19440610998
 WO1998DK00393
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.